Formulary Group Work Programme 2013
Forthcoming submissions.
This list is indicative and may be subject to change.
Infliximab - SMC 854/13 - in progress. (This SMC advice relates to an extension of the marketing authorisation to include use in children and adolescents aged 6 to 17 years for severely active ulcerative colitis).
Sugammadex (Bridion) - SMC 527/09 - in progress. (In this resubmission, the use of sugammadex for the routine reversal of moderate (shallow) or profound (deep) rocuronium- or vecuronium-induced neuromuscular blockade in the elective surgery setting is being considered).
Temocillin - indication: for the treatment of septicaemia, urinary tract infection and lower respiratory tract infection where susceptible gram-negative bacilli are suspected or confirmed (new drug request).
END